ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility of the AccuCinch® System for Left Ventricular Reshaping of the Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve Left Ventricular Function (LVRECOVER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02153892
Recruitment Status : Completed
First Posted : June 3, 2014
Last Update Posted : May 17, 2018
Sponsor:
Information provided by (Responsible Party):
Ancora Heart, Inc.

Brief Summary:
To assess the safety and performance of the GDS Accucinch System when used percutaneously to reduce functional mitral regurgitation.

Condition or disease Intervention/treatment Phase
Severe Functional Mitral Regurgitation and Heart Failure Device: GDS Accucinch System Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Protocol - A Feasibility Study Using the AccuCinch® System in the Left Ventricular Reshaping of the Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve Left Ventricular Function
Study Start Date : August 2014
Actual Primary Completion Date : October 2015
Actual Study Completion Date : January 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Multi-center, prospective, single-arm study
To assess the safety and performance of the GDS Accucinch System when used percutaneously to reduce functional mitral regurgitation.
Device: GDS Accucinch System
Percutaneous Coronary Intervention




Primary Outcome Measures :
  1. Procedural Success [ Time Frame: 72 hours post-procedure ]
    Successful use and implantation of an Accucinch System without Major Adverse Events (MAE) defined as the occurrence of any of the following: All-cause mortality, Device and/or procedure-related death; Peri-procedural myocardial infarction (MI) < or equal to 72 hrs after index procedure; Major stroke; Urgent or emergent conversion to surgery or repeat procedure (surgical or interventional therapy) for mitral valve or heart failure related deterioration; Left ventricular perforation; Major vascular complications; Major bleeding (including cardiac tamponade)

  2. Device Success [ Time Frame: 24 hours post-procedure ]
    Successful vascular access, delivery, and retrieval of the delivery system; Ability to establish access to the sub-annular groove, to deploy the Anchors, and the Anchor Links, to apply tension to the Cinch Cable, to reshape the mitral annulus, to deploy the Lock, and to cut the Cinch Cable; Intended performance of the Accucinch System measured by TTE acutely post-cinch with a reduction of MR by at least one grade

  3. Clinical Safety Measures [ Time Frame: 7 day post procedure ]
    Defined as freedom from MAE at discharge or 7 days post-procedure, whichever comes first; Safety measures will be reviewed and adjudicated by an independent clinical events committee (CEC); Echocardiographic measures will be assessed by an independent echocardiography core laboratory


Secondary Outcome Measures :
  1. Clinical Measure [ Time Frame: 30 day post-procedure ]
    NYHA Class improvement of at lease one score from baseline

  2. Echocardiographic Measures - Composite [ Time Frame: 30 days post-procedure ]
    Mitral Valve Measures: One grade reduction in MR (e.g. 3+ to 2+), or; Reduction in PISA EROA at least 25% from baseline, or; Reduction in Regurgitant Volume at least 25% Left Ventricular Measures: Reduction in Left Ventricular size (Left Ventricular End Diastolic Dimension - LVEDD) at least 5% from baseline, or: Reduction in Left Ventricular volume (Left Ventricular End Diastolic Volume -LVEDV) at least 5%, or Increase in ejection fraction (LVEF) at least 10% from baseline Left Atrial Measures: Left atrial volume index (biplane area-length method). The above echocardiographic measures will be assessed by an independent core laboratory

  3. Clinical Measure [ Time Frame: 30 day post-procedure ]
    6-minute walk test compared to baseline

  4. Clinical Measure [ Time Frame: 30 day post-procedure ]
    Quality of Life (KCCQ Questionnaire) compared to baseline


Other Outcome Measures:
  1. Additional Measures - Composite [ Time Frame: Collected at baseline, peri- and post-procedure, discharge or 7-days (whichever comes first) 30-day, 3, 6, and 12 months and at 2 and 3 years post procedure ]
    Safety measures (adjudicated by an independent Clinical Events Committee): Mortality: all-cause, cardiovascular, and non-cardiovascular; Spontaneous Myocardial Infarction (>72 hrs post-index procedure); Major and life-threatening bleeding; Major stroke: disabling and non-disabling; Major vascular complication (access site, non-access site); Acute Kidney Injury (< or equal to 72 hrs post-procedure): based on the modified RIFLE Stage 3 (including renal replacement therapy), Stage 2, and Stage 1; Failure of current therapy for functional mitral regurgitation requiring re-hospitalization or prolonged hospitalization for FMR-related symptoms and worsening heart failure with NYHA class III or IV, or requiring conversion to surgery; Anchor(s) migration or Anchor(s) dislocation (as assessed by fluoroscopic images or CT) (when applicable)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age > 18 years
  • Subjects with severe symptomatic functional mitral regurgitation of ≥ 3+ secondary to left ventricular (LV) remodeling and/or annular remodeling, as measured in accordance with the current ASE guidelines and suitable for treatment in accordance with the current AHA/ACC guidelines:

    • Left ventricular ejection fraction (LVEF) ≥ 20% and ≤ 40%
    • Stable cardiac medical regimen for heart failure for at least 1 month
    • Stable NYHA Classification (Class III and above) for at least 1 month
  • The subject has been informed of the nature of the study, agrees to its provisions, including the possibility of conversion to surgery, and has provided written informed consent.

Exclusion Criteria:

Candidates will be excluded from the study if any of the following conditions are present:

  • Myocardial infarction within 90 days of the intended treatment with the device
  • Prior surgical, transcatheter, or percutaneous mitral valve intervention or mitral valve prosthesis
  • Subject has untreated coronary artery disease, which in the opinion of the treating physician and/or heart team, is clinically significant and requires revascularization
  • Non-ambulatory NYHA Class IV symptoms of heart failure or subjects in cardiogenic shock or with hemodynamic instability requiring IV inotropic support or mechanical support devices
  • Subject has the need for emergent surgery for any reason
  • Subjects in whom sufficient quality of echocardiography (TTE and TEE) cannot be obtained
  • Echocardiography evidence of primary mitral valve disease causing MR or MS;
  • Moderate to severe pulmonary hypertension (PA systolic pressure ≥ 80 mm Hg) as assessed by echocardiography
  • Evidence of mitral valve stenosis with an estimated valve area less than 3.5 cm2
  • Mitral valve pathology that would prevent adequate function of the GDS Accucinch System
  • Subject is on dialysis or estimated GFR < 30mL/min/1.73m2 (Cockcroft-Gault Formula)d d Israni AK, et al. Laboratory Assessment of Kidney Disease, in Brenner and Rector's The Kidney, 9th ed. chapter 25
  • Greater than mild mitral annular calcification observed by fluoroscopy
  • Presence of aortic valve prosthesis
  • Moderate to severe aortic valve stenosis or calcification observed by echocardiography or fluoroscopy
  • Severe aortic arch calcification or mobile aortic atheroma observed by echocardiography or fluoroscopy
  • Active bacterial endocarditis or active sepsis
  • History of bleeding diathesis or coagulopathy
  • History of stroke within the prior 6 months
  • Subjects in whom anticoagulation is contraindicated
  • Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device
  • Concurrent medical condition with a life expectancy of less than 12 months
  • Currently participating in another investigational drug or device study that has not reached its primary endpoint
  • Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g. severe chronic obstructive pulmonary disease, hepatic failure, immunological abnormalities, and hematological abnormalities)
  • Subject with indication for concomitant surgery such as coronary artery bypass graft (CABG), aortic valve reconstruction or replacement, left ventricular remodeling surgery and congenital repair
  • Any cardiac resynchronization therapy within the last 9 months prior to treatment
  • Subject on high dose steroids or immunosuppressant therapy
  • Current problems with substance abuse (e.g. alcohol, illegal drugs, etc.)
  • Female subjects who are pregnant, lactating, or planning pregnancy within next the 36 months. Note: Childbearing age should be instructed to use safe contraception during their participation in this study.
  • Subjects who are unable or unwilling to comply with the follow-up schedule and requirements
  • Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated or has known hypersensitivity to study required medications, to nickel, or to polyurethanes
  • Femoral artery lumen diameter of < 5.5 mm, or severe ilio-femoral tortuosity or calcification that would prevent safe placement of the 16Fr introducer sheath

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02153892


Locations
Australia, Victoria
Monash Health
Melbourne, Victoria, Australia, 3168
Sponsors and Collaborators
Ancora Heart, Inc.
Investigators
Study Director: Michael Zapien Ancora Heart, Inc.

Responsible Party: Ancora Heart, Inc.
ClinicalTrials.gov Identifier: NCT02153892     History of Changes
Other Study ID Numbers: 3870
First Posted: June 3, 2014    Key Record Dates
Last Update Posted: May 17, 2018
Last Verified: May 2018

Keywords provided by Ancora Heart, Inc.:
Functional Mitral Regurgitation
Heart Failure
Ventricular Reshaping

Additional relevant MeSH terms:
Heart Failure
Mitral Valve Insufficiency
Heart Diseases
Cardiovascular Diseases
Heart Valve Diseases